A Phase 3 interventional study of idarubicin and microtransplantation in Acute Myeloid Leukemia, sponsored by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences. Status unknown at 1 site in China. Open to participants aged 7 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-07-13.
Sponsored by The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Phase 3, Interventional, and Treatment
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).
5,442 studies on the registry are indexed under Leukemia; 637 are open to participants now.
This study's planned enrollment of 50 is above the median of 38 across 4,248 interventional studies indexed under Leukemia.
Browse Leukemia studies →The Affiliated Hospital of the Chinese Academy of Military Medical Sciences is the lead sponsor of 25 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia
The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
Drug: idarubicin
The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
Biological: microtransplantation
idarubicin 10-12 mg/m2 for three days
idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
complete remission
Time frame: one year
disease-free survival
Time frame: three years
overall survival
Time frame: three years
This study is status unknown, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences